TSG Therapeutics ('TSG') is a preclinical-stage biopharmaceutical company on a mission to eliminate viral infectious diseases. The company has established a proven platform for developing drug candidates with potent antiviral activity against a wide range of infectious viral diseases, from Dengue and Zika, to Ebola and Rabies. TSG's ultimate goal is to produce a broad-spectrum therapeutic solution to viral diseases, effectively creating the 'penicillin for viruses'. Its current focus is mosquito-borne viral infections; among them, specifically 'Dengue' is the first target of TSG.